Emplozin SM 25 Tablet

Composition : Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg (extended release)

Dosage Form : Tablet

Packaging Type :

Packaging :

Price : ₹1/-

Please Contact For Best Price

Emplozin SM 25 Tablet is a combination therapy for the treatment of Type 2 diabetes mellitus in adults. It contains three active ingredients: Empagliflozin, Sitagliptin, and Metformin, each targeting different aspects of glucose regulation to help manage blood sugar levels effectively. This tablet is designed for patients who are not adequately controlled on diet, exercise, or other medications alone.

  • Empagliflozin (25mg) is an SGLT2 inhibitor, which reduces the reabsorption of glucose by the kidneys, allowing more glucose to be excreted in the urine, thus lowering blood sugar levels.
  • Sitagliptin (100mg) is a DPP-4 inhibitor that helps increase insulin production in response to meals and reduces glucose production by the liver.
  • Metformin (1000mg) is a biguanide that helps lower blood sugar by reducing liver glucose production and improving insulin sensitivity. The extended-release formulation minimizes gastrointestinal side effects while offering sustained glucose control throughout the day.

Together, these medications work synergistically to improve glycemic control, both in fasting and postprandial states. Emplozin SM 25 Tablet is recommended for patients with Type 2 diabetes who have not achieved optimal blood glucose levels through diet, exercise, and other oral medications. This combination helps manage blood sugar levels and reduces the risk of complications related to diabetes.

Read More

About the Product

Emplozin SM 25 Tablet is a combination therapy for the treatment of Type 2 diabetes mellitus in adults. It contains three active ingredients: Empagliflozin, Sitagliptin, and Metformin, each targeting different aspects of glucose regulation to help manage blood sugar levels effectively. This tablet is designed for patients who are not adequately controlled on diet, exercise, or other medications alone.

  • Empagliflozin (25mg) is an SGLT2 inhibitor, which reduces the reabsorption of glucose by the kidneys, allowing more glucose to be excreted in the urine, thus lowering blood sugar levels.
  • Sitagliptin (100mg) is a DPP-4 inhibitor that helps increase insulin production in response to meals and reduces glucose production by the liver.
  • Metformin (1000mg) is a biguanide that helps lower blood sugar by reducing liver glucose production and improving insulin sensitivity. The extended-release formulation minimizes gastrointestinal side effects while offering sustained glucose control throughout the day.

Together, these medications work synergistically to improve glycemic control, both in fasting and postprandial states. Emplozin SM 25 Tablet is recommended for patients with Type 2 diabetes who have not achieved optimal blood glucose levels through diet, exercise, and other oral medications. This combination helps manage blood sugar levels and reduces the risk of complications related to diabetes.

Possible side effects include nausea, headache, abdominal pain, dizziness, and risk of low blood sugar (especially when used with other anti-diabetic medications). Severe effects may include lactic acidosis or kidney problems.

For the treatment of Type 2 diabetes mellitus in adults to improve blood glucose control, alongside diet and exercise.

Not recommended for patients with severe kidney disease or diabetic ketoacidosis. Kidney function should be monitored regularly during treatment.

Get in Touch